Agios Pharmaceuticals Management

Management Kriterienprüfungen 0/4

Wichtige Informationen

Brian Goff

Geschäftsführender

US$3.4m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	23.4%
Amtszeit als Geschäftsführer	1.8yrs
Eigentum des Geschäftsführers	0.1%
Durchschnittliche Amtszeit des Managements	2.4yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	8yrs

Jüngste Management Updates

Recent updates

Agios Pharmaceuticals: Potential Acquisition Target, Upcoming FDA Approvals, Promising Pipeline

Jun 12

Companies Like Agios Pharmaceuticals (NASDAQ:AGIO) Are In A Position To Invest In Growth

Jun 02

Bearish: Analysts Just Cut Their Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Revenue and EPS estimates

Feb 17

Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation

Jan 16

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Trimmed Their Revenue Forecasts By 50%

Nov 09

Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation

Sep 26

Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 48%?

May 08

We're Hopeful That Agios Pharmaceuticals (NASDAQ:AGIO) Will Use Its Cash Wisely

Feb 06

Agios Pharmaceuticals (NASDAQ:AGIO) Is In A Good Position To Deliver On Growth Plans

Oct 18

Agios Pyrukynd for rare blood disorder gets EMA panel backing for approval in EU

Sep 16

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Trimmed Their Revenue Forecasts By 46%

Dec 21

Agios Pharmaceuticals: A Near-Term Capital Gain Prospect Seen By Market-Makers As Underpriced

Sep 07

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Brian Goff im Vergleich zu den Einnahmen von Agios Pharmaceuticals verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Mar 31 2024	n/a	n/a	-US$353m
Dec 31 2023	US$3m	US$798k	-US$352m
Sep 30 2023	n/a	n/a	-US$220m
Jun 30 2023	n/a	n/a	-US$210m
Mar 31 2023	n/a	n/a	-US$218m
Dec 31 2022	US$12m	US$308k	-US$232m

Geschäftsführer

Brian Goff (55 yo)

1.8yrs

Amtszeit

US$3,416,453

Vergütung

Mr. Brian M. Goff, M.B.A. is Chief Executive Officer and Director at Agios Pharmaceuticals, Inc. from August 08, 2022. He had been Executive Vice President at Alexion Pharmaceuticals, Inc. since June 01, 2...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Brian Goff	CEO & Director	1.8yrs	US$3.42m	0.12% $ 3.0m
Cecilia Jones	Chief Financial Officer	1.8yrs	US$1.21m	0.026% $ 654.6k
James Burns	Corporate Secretary & Chief Legal Officer	2.4yrs	US$1.93m	0.065% $ 1.6m
Sarah Gheuens	Chief Medical Officer and Head of Research & Development	2.8yrs	US$2.87m	0.069% $ 1.7m
Tsveta Milanova	Chief Commercial Officer	1.4yrs	US$3.73m	0.023% $ 583.7k
Lewis Cantley	Co-Founder & Member of Scientific Advisory Board	no data	US$333.51k	keine Daten
Tak Mak	Co-Founder & Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Craig Thompson	Co-Founder & Chairman of Scientific Advisory Board	no data	keine Daten	keine Daten
Shin-San Su	Co-Founder & Member of Scientific Advisory Board	no data	keine Daten	keine Daten
T. Washburn	Principal Accounting Officer	2.8yrs	keine Daten	0.0027% $ 67.1k
Clive Patience	Chief Technical Operations Officer	7yrs	keine Daten	keine Daten
Christopher J. Taylor	Vice President of Investor Relations & Corporate Communications	no data	keine Daten	keine Daten

2.4yrs

Durchschnittliche Betriebszugehörigkeit

55yo

Durchschnittliches Alter

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Brian Goff	CEO & Director	1.8yrs	US$3.42m	0.12% $ 3.0m
Lewis Cantley	Co-Founder & Member of Scientific Advisory Board	no data	US$333.51k	keine Daten
Tak Mak	Co-Founder & Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Craig Thompson	Co-Founder & Chairman of Scientific Advisory Board	no data	keine Daten	keine Daten
Shin-San Su	Co-Founder & Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Jacqualyn Fouse	Chair of the Board of Directors	6.5yrs	US$447.25k	0.24% $ 6.1m
Jeffrey Capello	Independent Director	less than a year	US$663.68k	keine Daten
Charles Sawyers	Member of Scientific Advisory Board	15.3yrs	keine Daten	keine Daten
Kaye Foster-Cheek	Lead Independent Director	9.5yrs	US$440.95k	0.014% $ 341.6k
David Schenkein	Independent Director	14.8yrs	US$417.25k	0.83% $ 20.9m
Matthew Vander Heiden	Member of Scientific Advisory Board	15.6yrs	keine Daten	keine Daten
Cynthia Smith	Independent Director	1.8yrs	US$419.91k	0.0040% $ 101.4k

8.0yrs

Durchschnittliche Betriebszugehörigkeit

65yo

Agios Pharmaceuticals Management

Management Kriterienprüfungen 0/4

Wichtige Informationen

Jüngste Management Updates

CEO & Director notifies of intention to sell stock

Agios Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

Chair of the Board of Directors exercised options and sold US$215k worth of stock

Independent Director notifies of intention to sell stock

Chair of the Board of Directors exercised options and sold US$232k worth of stock

CEO & Director exercised options and sold US$277k worth of stock

Recent updates

Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia in Plenary Session at the European Hematology Association 2024 Hybrid Congress

Forecast to breakeven in 2024

Agios Pharmaceuticals: Potential Acquisition Target, Upcoming FDA Approvals, Promising Pipeline

CEO & Director notifies of intention to sell stock

New minor risk - Share price stability

Agios Pharmaceuticals, Inc. Announces Phase 3 Energize-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia

Companies Like Agios Pharmaceuticals (NASDAQ:AGIO) Are In A Position To Invest In Growth

Consensus EPS estimates upgraded to US$3.16 loss

Price target increased by 13% to US$46.00

Consensus revenue estimates decrease by 33%, EPS upgraded

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Shareholder dilution

Agios Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

Chair of the Board of Directors exercised options and sold US$215k worth of stock

Independent Director notifies of intention to sell stock

Consensus revenue estimates increase by 46%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Bearish: Analysts Just Cut Their Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Revenue and EPS estimates

Consensus revenue estimates fall by 43%

Agios Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Chair of the Board of Directors exercised options and sold US$232k worth of stock

Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation

CEO & Director exercised options and sold US$277k worth of stock

Agios Pharmaceuticals, Inc. Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio

Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 2 Portion of the Rise Up Pivotal Study in Sickle Cell Disease at 65Th ASH Annual Meeting and Exposition

Agios Pharmaceuticals, Inc. Announces Clinical Proof-Of-Concept in Phase 2A Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Trimmed Their Revenue Forecasts By 50%

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Agios Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Agios Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

CEO & Director exercised options and sold US$325k worth of stock

Agios Pharmaceuticals, Inc. Announces Board Changes

Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 48%?

Director exercised options and sold US$226k worth of stock

Director exercised options and sold US$262k worth of stock

Director exercised options and sold US$269k worth of stock

Director exercised options and sold US$326k worth of stock

Chair of the Board of Directors exercised options and sold US$105k worth of stock

We're Hopeful That Agios Pharmaceuticals (NASDAQ:AGIO) Will Use Its Cash Wisely

Director exercised options and sold US$406k worth of stock

Director notifies of intention to sell stock

Insider exercised options and sold US$79k worth of stock

Agios Pharmaceuticals, Inc. Presents Updated PYRUKYND® (mitapivat) Long-term Extension Data Demonstrating Sustained Clinical Benefits in Adults with Pyruvate Kinase (PK) Deficiency at 64th ASH Annual Meeting and Exposition

Agios Pharmaceuticals, Inc. Appoints Tsveta Milanova as Chief Commercial Officer, Effective Jan. 3, 2023

Price target decreased to US$36.20

Price target increased to US$39.20

Agios Pharmaceutical's PYRUKYND® Approves in the EU for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients

Consensus forecasts updated

Agios Pharmaceuticals (NASDAQ:AGIO) Is In A Good Position To Deliver On Growth Plans

Agios Pharmaceuticals, Inc. Appoints Cecilia Jones as Chief Financial Officer, Effective September 26, 2022

Agios Pharmaceuticals, Inc. Receives Positive Chmp Opinion for Pyrukynd® (Mitapivat) for the Treatment of Pyruvate Kinase (Pk) Deficiency in Adult Patients

Agios Pyrukynd for rare blood disorder gets EMA panel backing for approval in EU

Agios Pharmaceuticals, Inc. Announces Resignation of Jonathan Biller as Chief Financial Officer, Effective September 16, 2022

Agios adds more than 13% after Novo deal to acquire rival Forma

Agios Pharmaceuticals, Inc. Appoints Rahul Ballal and Cynthia Smith to Board of Directors

Agios Pharmaceuticals, Inc. Announces Publication of Phase 2 Data in The Lancet Demonstrating Safety and Efficacy of PYRUKYND® (mitapivat) in Non-transfusion-dependent a- and ß-Thalassemia

Insufficient new directors

Agios Pharmaceuticals GAAP EPS of -$1.68 beats by $0.07

Agios Pharmaceuticals Is A Buy On Coming Revenue Ramp

Agios Pharmaceuticals, Inc. Announces Management Changes, Effective August 8, 2022

Agios Pharmaceuticals appoints new board chair, CEO

Agios Presents New Clinical Data Supporting the Benefits of Pyrukynd® Treatment in Adults with PK Deficiency At European Hematology Association Annual Congress

Agios Pharmaceuticals, Inc. Announces Resignation of Bruce Car as Chief Scientific Officer, effective as of August 1, 2022

Agios Pharmaceuticals, Inc. Announces Management Changes

Agios Pharmaceuticals, Inc. Announces Executive Changes

Consensus forecasts updated

Agios: Approved Product, Upcoming Catalysts